J. Anabuki

A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.

Kumiko Yoshida, Sayaka Fukuda-Tsuru, J. Anabuki, 2012, European journal of pharmacology.

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

H. Utsumi, S. Kiuchi, Yoshinobu Nakamaru, 2012, Bioorganic & medicinal chemistry.

Muscarinic stimulation does not induce rhoA/ROCK-mediated Ca2+ sensitization of the contractile element in chicken gizzard smooth muscle

H. Ozaki, M. Hori, H. Karaki, 2000, Pflügers Archiv.

Mechanisms of pinacidil-induced vasodilatation.

H. Ozaki, M. Hori, H. Karaki, 1990, European journal of pharmacology.

Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor MT-3014 in rats

K. Hashimoto, Koki Kojima, Takeaki Saijo, 2020, Pharmacology Biochemistry and Behavior.

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

H. Utsumi, S. Kiuchi, Yoshinobu Nakamaru, 2012, Bioorganic & medicinal chemistry.